CLINICAL_TRIALS
trial_result
· 2022-09-27
Clinical Trial Update: Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes [Phase 3]
Summary
Phase 3 trial assessing alirocumab's effect on postprandial hyperlipemia in patients with type 2 diabetes has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nantes University Hospital | Conditions: Type2 Diabetes | Phase 3 | Status: COMPLETED